Misonidazole

CAS No. 13551-87-6

Misonidazole ( —— )

Catalog No. M27482 CAS No. 13551-87-6

Misonidazole as a novel GPX inhibitors to cause oxidative stress in chemotherapy-resistant tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 38 Get Quote
5MG 61 Get Quote
10MG 87 Get Quote
25MG 147 Get Quote
50MG 219 Get Quote
100MG 329 Get Quote
200MG 485 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Misonidazole
  • Note
    Research use only, not for human use.
  • Brief Description
    Misonidazole as a novel GPX inhibitors to cause oxidative stress in chemotherapy-resistant tumors.
  • Description
    Misonidazole as a novel GPX inhibitors to cause oxidative stress in chemotherapy-resistant tumors.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Cereblon;CDK4;CDK6
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    13551-87-6
  • Formula Weight
    201.2
  • Molecular Formula
    C7H11N3O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COCC(Cn1c([N+]([O-])=O)ncc1)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Jian Jin, et al. Compositions and methods for treating cdk4/6-mediated cancer. WO2018106870A1.
molnova catalog
related products
  • Algestone acetopheni...

    Algestone acetophenide is progesterone that used in estrus synchronization and has been evaluated as an injectable contraceptive in combination with estradiol enanthate.

  • SR8278

    SR8278 is an REV-ERBα antagonist(EC50 = 0.47 μM) blocking activation of the receptor by the synthetic agonist GSK 4112.

  • Talatisamine

    Talatisamine (12 μM) and TEA (5mM) inhibits the enhanced I(K) caused by Aβ4 oligomers, attenuates cytotoxicity of Aβ oligomers by restoring cell viability and suppressing K(+) loss related apoptotic response.